Document Detail

Coronary stenting versus balloon angioplasty for acute myocardial infarction: a meta-regression analysis of randomized trials.
MedLine Citation:
PMID:  17544528     Owner:  NLM     Status:  MEDLINE    
INTRODUCTION: Although stenting has been shown to reduce the need for target vessel revascularization (TVR) in acute myocardial infarction (AMI), the benefits in terms of mortality and reinfarction are still unclear. Previous meta-analyses have failed to include all currently available randomized trials. The aim of the current study was to perform an updated meta-analysis to evaluate the benefits of coronary stenting for AMI in terms of mortality, reinfarction, and TVR, and whether these benefits correlated with the patient's risk profile. METHODS: The literature was scanned by formal searches of electronic databases (MEDLINE and CENTRAL) from January 1990 to September 2006. We examined all completed, published, randomized trials of coronary stenting for AMI. The following key words were used for study selection: randomized trial, myocardial infarction, reperfusion, primary angioplasty, rescue angioplasty, stenting, and balloon angioplasty. Information on study design, type of stent, inclusion and exclusion criteria, primary endpoint, number of patients, angiographic and clinical outcome, were extracted by two investigators. Disagreements were resolved by consensus. RESULTS: A total of 13 randomized trials were identified and analyzed involving 6922 patients (3460 or 50% randomized to stent and 3462 or 50% to balloon). Stenting was not associated with a significant reduction in 30-day (2.9% versus 3.0%, p=0.81) and 1-year mortality (5.1% versus 5.2%, p=0.81), as compared to balloon angioplasty. However, a significant relationship was observed between patient's risk profile and mortality benefits from coronary stenting at 30-day (beta -0.63 [-25.4; -2.45], p=0.022) and 1-year follow-up (beta -0.61 [-15.9; -0.76], p=0.034). Stenting was associated with benefits in terms of TVR at both 30-day (3.1% versus 5.1%, p<0.0001) and 6 to 12 months (11.3% versus 18.4%, p<0.0001) follow-up, without any difference in terms of reinfarction. CONCLUSIONS: Among AMI patients undergoing primary angioplasty, coronary stent implantation, when anatomically and technically feasible, may be considered, in addition to benefits in terms of TVR, to reduce mortality in high-risk patients, who may be identified by the use of validated risk scores.
Giuseppe De Luca; Harry Suryapranata; Gregg W Stone; David Antoniucci; Giuseppe Biondi-Zoccai; Adnan Kastrati; Massimo Chiariello; Paolo Marino
Related Documents :
14664288 - Abciximab for the treatment of an acute thrombotic coronary occlusion during stent impl...
7801858 - Intracoronary stenting in the treatment of acute or threatened closure in angiographica...
19124388 - Drug-eluting stent thrombosis.
12667408 - Efficacy of recombinant tissue-type plasminogen activator thrombolysis and primary coro...
25223478 - Discrimination of thoracic vein potentials facilitated by atrial pacing during the isol...
17659918 - Effect of hyponatremia (<135 meq/l) on outcome in patients with non-st-elevation acute ...
Publication Detail:
Type:  Comparative Study; Journal Article; Meta-Analysis     Date:  2007-06-04
Journal Detail:
Title:  International journal of cardiology     Volume:  126     ISSN:  1874-1754     ISO Abbreviation:  Int. J. Cardiol.     Publication Date:  2008 May 
Date Detail:
Created Date:  2008-04-21     Completed Date:  2008-09-15     Revised Date:  2009-04-16    
Medline Journal Info:
Nlm Unique ID:  8200291     Medline TA:  Int J Cardiol     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  37-44     Citation Subset:  IM    
Division of Cardiology, Maggiore della Carità Hospital, Eastern Piedmont University, C.So Mazzini, 18, 24100 Novara, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angioplasty, Balloon / adverse effects,  methods*,  mortality,  statistics & numerical data
Coronary Restenosis / etiology,  mortality
Coronary Vessels* / pathology
Myocardial Infarction / mortality,  therapy*
Randomized Controlled Trials as Topic / methods,  statistics & numerical data
Regression Analysis
Risk Factors
Stents* / adverse effects
Comment In:
Int J Cardiol. 2009 Apr 17;133(3):394-6; author reply 396   [PMID:  18077019 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Comments on the article by Abboud et al. "Peripartum cardiomyopathy: a comprehensive review": a trib...
Next Document:  Postmortem molecular analysis of KCNQ1 and SCN5A genes in sudden unexplained death in young Australi...